Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Rhea-AI Summary
Cartesian Therapeutics (NASDAQ: RNAC) reported Q1 2026 results and pipeline updates. Cash, cash equivalents and restricted cash were $120.4 million as of March 31, 2026, after raising $14.6 million via its ATM program, expected to fund operations into mid-2027, including completion of the Phase 3 AURORA trial.
Clinical progress: enrollment continues in the randomized Phase 3 AURORA trial (~100 AChR Ab+ MG patients), Phase 2 TRITON in dermatomyositis/antisynthetase syndrome initiated, and multiple patients enrolled in the Phase 1/2 HELIOS pediatric trial (JDM); Descartes-08 has FDA Rare Pediatric Disease Designation for JDM. Q1 R&D was $19.5M, G&A $7.1M, and net loss was $39.2M (net loss per share $1.46).
AI-generated analysis. Not financial advice.
Positive
- $120.4M cash position as of March 31, 2026
- Raised $14.6M via ATM offering in Q1 2026
- Phase 3 AURORA enrollment progressing in ~100 AChR Ab+ MG patients
- Initiated randomized Phase 2 TRITON in dermatomyositis and antisynthetase syndrome
- Multiple patients enrolled in Phase 1/2 HELIOS pediatric trial; FDA Rare Pediatric Disease Designation for JDM
Negative
- Net loss widened to $39.2M in Q1 2026 from $17.7M in Q1 2025
- R&D spend increased to $19.5M reflecting Phase 3 AURORA costs
- Cash runway expected only into mid-2027, limiting long-term visibility
News Market Reaction – RNAC
On the day this news was published, RNAC declined 3.86%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.9% from its starting point during tracking. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $181.97M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RNAC fell 4.85% while key peers showed mixed, mostly modest moves (e.g., CADL -0.48%, AVIR -2.16%, DBVT -3.01%, NMRA +0.45%, OMER -0.55%), suggesting a company-specific move rather than a broad sector swing.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | Full-year 2025 earnings | Positive | +31.7% | Strong cash, runway into mid-2027 and Descartes-08 pipeline progress. |
| Nov 06 | Q3 2025 earnings | Positive | -1.6% | Solid cash runway and AURORA progress but higher net loss reported. |
| Aug 07 | Q2 2025 earnings | Positive | -6.6% | Phase 3 AURORA initiation and strong cash with one-time net income. |
| May 08 | Q1 2025 earnings | Positive | +2.7% | Promising Descartes-08 MG data and plan for Phase 3 AURORA. |
| Mar 13 | Full-year 2024 earnings | Positive | -5.0% | Lower R&D and G&A with strong cash and Phase 3 planning. |
Earnings updates often highlight strong cash and pipeline progress, but price reactions have been mixed, with more instances of downside than upside moves following these announcements.
Over the past year, RNAC’s earnings releases have consistently emphasized a strong cash position and funding runway into mid-2027 alongside steady advancement of the Descartes‑08 program, including initiation and enrollment of the Phase 3 AURORA trial and expansion into myositis and pediatric indications. Market reactions have varied, from a 31.68% rise on the full‑year 2025 update to several negative responses when higher losses or spending were reported, underscoring investor sensitivity to the balance between R&D investment and dilution risk.
Historical Comparison
Past earnings-related updates for RNAC moved the stock an average of 4.25%, with reactions split between strong rallies and notable selloffs as investors weighed cash runway against rising losses.
Earnings releases show a steady evolution from planning Descartes‑08 Phase 3 AURORA to active enrollment, while pivoting away from earlier programs and adding TRITON and HELIOS trials as the autoimmune pipeline matures.
Market Pulse Summary
This announcement underscores Cartesian’s strategy of funding an expanding Descartes‑08 program while maintaining a cash runway into mid-2027. Q1 2026 showed higher R&D spending at $19.5 million, lower G&A at $7.1 million, and a net loss of $39.2 million, partly supported by $14.6 million raised via ATM. Investors may focus on execution in the Phase 3 AURORA, Phase 2 TRITON, and HELIOS trials and on the trajectory of operating expenses and capital raises in future updates.
Key Terms
bcma medical
car-t medical
mg-adl medical
rare pediatric disease designation regulatory
atm offering financial
AI-generated analysis. Not financial advice.
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis
Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated
Multiple patients enrolled in Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis
Approximately
FREDERICK, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“we”, the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026, and outlined recent business updates.
“Descartes-08 represents a significant opportunity to address the many unmet needs of patients living with autoimmune diseases, with the potential to simultaneously improve quality of life through depth and durability of response. With three clinical programs in progress, we remain focused on advancing this mission with near-term milestones across our pipeline,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “We continue to prioritize our myasthenia gravis (MG) program as we enroll patients into the Phase 3 AURORA trial. In parallel, we initiated our Phase 2 TRITON trial of adult patients with dermatomyositis and antisynthetase syndrome. We have also enrolled multiple patients in the Phase 1/2 HELIOS pediatric trial in juvenile dermatomyositis (JDM) and are encouraged by the early enrollment observed to-date. The momentum across all three programs strengthens our conviction in Descartes-08’s promise as we advance it toward its full potential.”
Pipeline Progress and Anticipated Milestones
- Enrollment Continues to Progress in the Phase 3 AURORA Trial of Descartes-08 in Participants with MG. The randomized, double-blind, placebo-controlled Phase 3 AURORA trial is designed to assess Descartes-08, Cartesian’s autologous anti-B cell maturation antigen (BCMA) chimeric antigen receptor T-cell therapy (CAR-T) versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 patients with acetylcholine receptor autoantibody positive (AChR Ab+) MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living (MG-ADL) score of three points or more at Month 4 compared to placebo.
- Phase 2 TRITON Trial Initiated in Myositis. The randomized, double-blind, placebo-controlled Phase 2 TRITON trial in myositis is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six weekly outpatient infusions without preconditioning chemotherapy in patients with moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome. The primary endpoint is expected to assess safety and efficacy of Descartes-08 compared to placebo added to standard of care in participants with myositis at Week 24. The Company plans to evaluate the first 10 patients from the study to determine the path to a pivotal trial in this indication with significant unmet need.
- Multiple Patients Enrolled in Phase 1/2 HELIOS Pediatric Trial of Descartes-08 in Autoimmune Diseases, Including JDM. In January 2026, Cartesian announced the initiation of its Phase 1/2 HELIOS pediatric trial of Descartes-08 in children and young adults with autoimmune diseases, including JDM. JDM is a rare pediatric autoimmune disorder marked by pathognomonic skin rash and muscle inflammation affecting multiple organ systems. The FDA previously granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of JDM.
Full Year 2026 Financial Results
- Cash, cash equivalents and restricted cash as of March 31, 2026 was
$120.4 million . During the first quarter of 2026, the Company raised$14.6 million after commissions and expenses through its active at the market (ATM) offering program. The Company’s current cash resources on hand are expected to support planned operations, including completion of the ongoing Phase 3 AURORA trial, into mid-2027. - Research and development expenses were
$19.5 million for the three months ended March 31, 2026, compared to$14.7 million for the three months ended March 31, 2025. The increase was primarily a result of increased expenses associated with the ongoing Phase 3 AURORA trial, partially offset by a decrease in expenses for early stage programs, primarily related to the decision to no longer pursue development of Descartes-08 in systematic lupus erythematosus. - General and administrative expenses were
$7.1 million for the three months ended March 31, 2026, compared to$8.3 million for the three months ended March 31, 2025. The decrease was primarily the result of lower professional and consulting fees. - Net loss was
$39.2 million , or$1.46 net loss per share allocable to common stockholders (basic), for the three months ended March 31, 2026, compared to net loss of$17.7 million , or$0.68 net loss per share allocable to common stockholders (basic), for the three months ended March 31, 2025.
About Descartes-08
Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous CAR-T product targeting BCMA in clinical development for generalized MG and myositis, specifically dermatomyositis and antisynthetase syndrome. In contrast to conventional DNA-based CAR T-cell therapies, Cartesian’s CAR-T administration is designed to not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation. Descartes-08 has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation by the U.S. Food and Drug Administration for the treatment of MG, and Rare Pediatric Disease Designation for the treatment of JDM.
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
Forward Looking Statements
Any statements in this press release about the future expectations, plans and prospects of the Company, including without limitation, statements regarding the Company’s expected cash resources and cash runway, the ability of the Company’s product candidates to be administered in an outpatient setting or without the need for preconditioning lymphodepleting chemotherapy, the potential of Descartes-08, or any of the Company’s other product candidates to treat MG, juvenile MG, myositis, JDM, or any other disease, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, including the ongoing Phase 3 AURORA trial of Descartes-08 in MG, the ongoing Phase 2 TRITON trial of Descartes-08 in myositis, and the ongoing Phase 1/2 HELIOS pediatric trial of Descartes-08 in autoimmune diseases, including JDM, the anticipated timing or the outcome of the FDA’s review of the Company’s regulatory filings, including the number of trials that may be necessary in order to obtain marketing approval, the potential for in-vivo delivery of the Company’s product candidates, the Company’s ability to conduct its clinical trials and preclinical studies, the timing or making of any regulatory filings, the anticipated timing or outcome of selection of developmental product candidates, the ability of the Company to enter into and maintain potential collaborations or partnerships, the novelty of treatment paradigms that the Company is able to develop, the potential of any therapies developed by the Company to fulfill unmet medical needs, and enrollment in the Company’s clinical trials and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company’s technology, potential delays in enrollment of patients, undesirable side effects of the Company’s product candidates, political uncertainty, the Company’s reliance on third parties to conduct its clinical trials, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows, substantial fluctuation in the price of the Company’s common stock, risks related to geopolitical conflicts, pandemics, and macroeconomic impacts, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release, except as required by law.
| Cartesian Therapeutics, Inc. and Subsidiaries Consolidated Balance Sheets (Amounts in thousands, except share data and par value) | |||||||
| March 31, | December 31, | ||||||
| 2026 | 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 118,641 | $ | 125,139 | |||
| Accounts receivable | 261 | 1,115 | |||||
| Prepaid expenses and other current assets | 3,137 | 3,022 | |||||
| Total current assets | 122,039 | 129,276 | |||||
| Property and equipment, net | 11,637 | 12,185 | |||||
| Right-of-use assets, net | 5,366 | 5,601 | |||||
| In-process research and development asset | 93,900 | 93,900 | |||||
| Goodwill | 48,163 | 48,163 | |||||
| Long-term restricted cash | 1,735 | 1,735 | |||||
| Long-term prepaid expenses and other assets | 5,551 | 5,551 | |||||
| Total assets | $ | 288,391 | $ | 296,411 | |||
| Liabilities and stockholders’ deficit | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,598 | $ | 1,288 | |||
| Accrued expenses and other current liabilities | 10,161 | 9,498 | |||||
| Lease liabilities | 4,186 | 4,151 | |||||
| Total current liabilities | 15,945 | 14,937 | |||||
| Lease liabilities, net of current portion | 7,669 | 8,525 | |||||
| Warrant liability | 47 | 141 | |||||
| Contingent value right liability | 405,900 | 392,100 | |||||
| Deferred tax liabilities, net | 6,948 | 6,948 | |||||
| Total liabilities | 436,509 | 422,651 | |||||
| Stockholders’ deficit: | |||||||
| Series A Preferred Stock, | — | — | |||||
| Series B Preferred Stock, | — | — | |||||
| Preferred stock, | — | — | |||||
| Common stock, | 3 | 3 | |||||
| Additional paid-in capital | 718,017 | 700,706 | |||||
| Accumulated deficit | (861,555 | ) | (822,373 | ) | |||
| Accumulated other comprehensive loss | (4,583 | ) | (4,576 | ) | |||
| Total stockholders’ deficit | (148,118 | ) | (126,240 | ) | |||
| Total liabilities and stockholders’ deficit | $ | 288,391 | $ | 296,411 | |||
| Cartesian Therapeutics, Inc. and Subsidiaries Consolidated Statements of Operations and Comprehensive Loss (Amounts in thousands, except share and per share data) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Revenues: | |||||||
| Collaboration and license | $ | — | $ | 400 | |||
| Grant | 78 | 700 | |||||
| Total revenues | 78 | 1,100 | |||||
| Operating expenses: | |||||||
| Research and development | 19,463 | 14,674 | |||||
| General and administrative | 7,114 | 8,315 | |||||
| Total operating expenses | 26,577 | 22,989 | |||||
| Operating loss | (26,499 | ) | (21,889 | ) | |||
| Other (expense) income: | |||||||
| Interest income | 1,026 | 2,015 | |||||
| Gain on change in fair value of warrant liabilities | 94 | 1,818 | |||||
| Loss on change in fair value of contingent value right liability | (13,800 | ) | 346 | ||||
| Other expense, net | (3 | ) | — | ||||
| Total other (expense) income, net | (12,683 | ) | 4,179 | ||||
| Net loss | $ | (39,182 | ) | $ | (17,710 | ) | |
| Other comprehensive (loss) income: | |||||||
| Foreign currency translation adjustment | (7 | ) | 32 | ||||
| Total comprehensive loss | $ | (39,189 | ) | $ | (17,678 | ) | |
| Net loss | $ | (39,182 | ) | $ | (17,710 | ) | |
| Net loss per share allocable to common stockholders: | |||||||
| Basic and diluted | $ | (1.46 | ) | $ | (0.68 | ) | |
| Weighted-average common shares outstanding: | |||||||
| Basic and diluted | 26,855,158 | 25,902,650 | |||||
Investor Contact
Megan LeDuc
Associate Director of Investor Relations
megan.leduc@cartesiantx.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
